It has been stated by Professor Robert Howard at the King's College London Institute of Psychiatry through a study that was funded by the Alzheimer's Society and the Medical Research Council, that there might be more efficiency in the drug donepezil when it is used treating people who have dementia and mild to moderate Alzheimer's Disease.
Around the world about 750,000 people are targeted by dementia and these people are those who are moderate to severe cases of dementia.
As compared to the number of people being treated now, with this breakthrough about twice the number of people might get treated with this drug.
Two drugs known as memantine and donepezil were analyzed during the trial by researchers. For people who are in the early stages of Alzheimer's, doctors gave donepezil previously, and even now for treating dementia it is the most prevalent drug.
Due to no evidence that could prove the effectiveness of the drug while treating people with dementia in later stages, doctors are told not to prescribe donepezil after the early stages of dementia.
Professor Robert Howard, from the Institute of Psychiatry at King's, and lead researcher of the study said, "As patients progress to more sever forms of Alzheimer's disease, clinicians are faced with a difficult decision as to whether to continue or not with dementia drugs and, until now, there has been little evidence to guide that decision."